A new drug (CX11) for blood sugar control in type 2 diabetes

You may qualify if

• Adults aged 18 to 75.
• Diagnosis of type 2 diabetes for at least 6 months.
• HbA1c between 7.0% and 10.5%.
• Body mass index (BMI) between 23 and 50 kg/m².
• Body weight stable for the past 3 months before joining.
• Stable dose of metformin (≥1000 mg/day), with or without SGLT2i, for ≥3 months.
• Women of childbearing potential (WOCBP): highly effective contraception ≥6 months prior to screening, throughout study, and 90 days post-last dose; negative pregnancy test within 24 hrs of first dose; no intent to donate sperm/ova
• Agrees to avoid grapefruit/grapefruit products

You can't join if

• Anticipated initiation or change in concomitant medications (for more than 14 consecutive days) known to affect weight or glucose metabolism (e.g. treatment with orlistat, thyroid hormones, or systemic corticosteroids).
• Type 1 diabetes or a history of diabetic ketoacidosis.
• Use of any GLP-1 receptor agonist within the past 6 months, or any prior exposure to CX11.
• Use of insulin to control blood sugar within the past 12 months.
• More than one episode of severe low blood sugar, with awareness of hypoglycemia symptoms.
• Cardiovascular or cerebrovascular conditions within the past 6 months:; Heart attack, coronary angioplasty, or bypass surgery (diagnostic angiography allowed).; Valvular heart disease or prior heart valve repair surgery.; Unstable angina.; Transient ischemic attack (TIA) or stroke.; Decompensated heart failure (NYHA Class III or IV).; ECG abnormalities indicating significant safety risk, such as supraventricular tachycardia, torsades de pointes, second- or third-degree AV block, myocardial infarction, QTcF > 450 ms in males or > 470 ms in females, PR interval > 220 ms.; Poorly controlled hypertension at screening: systolic ≥ 180 mmHg or diastolic ≥ 100 mmHg.
• Pancreatic or gallbladder conditions:; Acute or chronic pancreatitis.; Symptomatic gallbladder disease (previous cholecystectomy is allowed).; Pancreatic injury or risk factors that increase pancreatitis risk.
• Thyroid conditions:
• Poorly controlled abnormal thyroid function on a stable dose before screening.
• Clinically significant abnormal thyroid test results at screening.
• Personal or first-degree family history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) type 2A or 2B.
• Cancer history:
• Malignancy within the past 5 years, regardless of recurrence or metastasis. Exceptions: localized basal cell skin cancer, low-risk prostate cancer, cervical carcinoma in situ, or high-grade prostatic intraepithelial neoplasia.
• Gastrointestinal conditions or treatments that may affect drug absorption:; Abnormal gastric emptying (e.g., gastric outlet obstruction).; Severe chronic gastrointestinal disease, including active ulcer within 6 months.; Crohn's disease, ulcerative colitis, or other inflammatory bowel diseases.; Prior gastrointestinal surgery (except polypectomy and appendectomy).; Long-term use of drugs that directly affect gastrointestinal motility (e.g., mosapride, cisapride).
• Liver disease:
• Active liver disease other than nonalcoholic fatty liver.
• Chronic active hepatitis B or C.
• Primary biliary cirrhosis.
• Eye disease:
• Uncontrolled or potentially unstable diabetic retinopathy or maculopathy.
• Abnormal lab results at screening:; eGFR < 60 mL/min/1.73 m² (CKD-EPI).; ALT or AST > 2.5 × upper limit of normal (ULN).; Total bilirubin > 1.5 × ULN (except known Gilbert's syndrome).; Serum amylase or lipase > 1.5 × ULN.; Fasting triglycerides > 5.7 mmol/L.; TSH > 1.5 × ULN or < 1.0 × LLN.; Calcitonin ≥ 20 ng/L.; Hemoglobin < 110 g/L (male) or < 100 g/L (female).